Late last week, the FDA approved an sBLA for unbranded labeling for AbbVie’s megablockbuster Humira (adalimumab), opening the door for a potential new way to continue to hold onto the tens of billions of dollars it pulls in every year from sales of the medication. The…
Click here to view original post
